Silverback Therapeutics (SBTX) began trading on the Nasdaq on Fri 4 Dec 20

Update Jul 21, 2022:  Seattle-based Silverback Therapeutics will merge with another biotech company, San Diego-based ARS Pharmaceuticals.

*****

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers.

• Sector(s): Healthcare
• Industry: Biotechnology
• founded in 2016 
• Headquartered in Seattle, Washington
• http://www.silverbacktx.com

Silverback Therapeutics (SBTX) priced 11.5 mln share IPO at $21.00 per share,above the $17-19 expected range. Opened for trading at $29.